Format

Send to

Choose Destination
Semin Cancer Biol. 2015 Dec;35:53-61. doi: 10.1016/j.semcancer.2015.09.002. Epub 2015 Sep 7.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Author information

1
INRIA, Team MONC, Institut de mathématiques de Bordeaux UMR 5251, Université de Bordeaux, Talence, France.
2
Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Children's Cancer Institute, Randwick, Australia.
3
INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France.
4
INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France.
5
INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Oncologie Multidisciplinaire et d'Innovations Thérapeutiques, Nord University Hospital of Marseille, Marseille, France.
6
Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Hematologie et Oncologie Pediatrique, La Timone Hospital, Marseille, France.
7
Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France. Electronic address: joseph.ciccolini@univ-amu.fr.

Abstract

Oncology has benefited from an increasingly growing number of groundbreaking innovations over the last decade. Targeted therapies, biotherapies, and the most recent immunotherapies all contribute to increase the number of therapeutic options for cancer patients. Consequently, substantial improvements in clinical outcomes for some disease with dismal prognosis such as lung carcinoma or melanoma have been achieved. Of note, the latest innovations in targeted therapies or biotherapies do not preclude the use of standard cytotoxic agents, mostly used in combination. Importantly, and despite the rise of bioguided (a.k.a. precision) medicine, the administration of chemotherapeutic agents still relies on the maximum tolerated drug (MTD) paradigm, a concept inherited from theories conceptualized nearly half a century ago. Alternative dosing schedules such as metronomic regimens, based upon the repeated and regular administration of low doses of chemotherapeutic drugs, and adaptive therapy (i.e. modulating the dose and frequency of cytotoxics administration to control disease progression rather than eradicate it at all cost) have emerged as possible strategies to improve response rates while reducing toxicities. The recent changes in paradigm in the way we theorize cancer biology and evolution, metastatic spreading and tumor ecology, alongside the recent advances in the field of immunotherapy, have considerably strengthened the interest for these alternative approaches. This paper aims at reviewing the recent evolutions in the field of theoretical biology of cancer and computational oncology, with a focus on the consequences these changes have on the way we administer chemotherapy. Here, we advocate for the development of model-guided strategies to refine doses and schedules of chemotherapy administration in order to achieve precision medicine in oncology.

KEYWORDS:

Mathematical modeling; Metronomic chemotherapy; PK/PD; Precision medicine

PMID:
26361213
DOI:
10.1016/j.semcancer.2015.09.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center